Get started
Author

R Wang

Observed name: Rong Wang
Observed institution: Pfizer (United States)
OpenAlex ID: A5139535303
Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
2026 · T Damy, P Garcia-Pavia, et al. · European Journal of Heart Failure · 1
PDF
Improvements in cardiac functional status and health-related quality of life in patients receiving early access tafamidis
2026 · M G Crespo-Leiro, N M Fine, et al. · European Journal of Heart Failure
Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy
2026 · R Witteles, D Delgado, et al. · European Journal of Heart Failure
26-a-9815-acc Relative Importance of Markers of Progression in Patients With Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Post-hoc Analysis
2026 · Pablo Garcia Pavia, Mazen A. Hanna, et al. · Journal of the American College of Cardiology
Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
2025 · T Damy, R Witteles, et al. · European Heart Journal
Works count: 5
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type